TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction

Cardiac fibroblast (CF) differentiation into myofibroblasts is a crucial driver of cardiac fibrosis, leading to extensive extracellular matrix (ECM) deposition that increases myocardial stiffness and eventually impairs heart function. Mechanotransduction has merged as a key regulator of CF activatio...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Liu, Jingjing Feng, Jingxuan Zhao, Xiangjie Kong, Zhangyi Yu, Yuanru Huang, Zechun He, Mengxin Liu, Zheng Liu, Zhibing Lu, Li Wang
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Cell Insight
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2772892725000306
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849416751088926720
author Jie Liu
Jingjing Feng
Jingxuan Zhao
Xiangjie Kong
Zhangyi Yu
Yuanru Huang
Zechun He
Mengxin Liu
Zheng Liu
Zhibing Lu
Li Wang
author_facet Jie Liu
Jingjing Feng
Jingxuan Zhao
Xiangjie Kong
Zhangyi Yu
Yuanru Huang
Zechun He
Mengxin Liu
Zheng Liu
Zhibing Lu
Li Wang
author_sort Jie Liu
collection DOAJ
description Cardiac fibroblast (CF) differentiation into myofibroblasts is a crucial driver of cardiac fibrosis, leading to extensive extracellular matrix (ECM) deposition that increases myocardial stiffness and eventually impairs heart function. Mechanotransduction has merged as a key regulator of CF activation and the fibrotic response post-myocardial infarction (MI). However, the molecular mechanisms linking CF activation to mechanical cues within the injured myocardium remain poorly understood. Here we identified transcription factor TFAP4 as a central regulator of fibrosis in both human and murine models. TFAP4 overexpression enhances CF proliferation, ECM protein expression, and myofibroblast differentiation. Notably, TFAP4 directly activates expression of mechanosensors including Itga11 and Piezo2, which are essential for transmitting mechanical signals that promote CF activation and fibrosis. Silencing Itga11 and Piezo2 reverses the pro-fibrotic effects of TFAP4, while TFAP4 downregulation in vivo reduces fibrosis and improves cardiac function post-MI. These findings identify TFAP4 as a pivotal link between mechanotransduction and fibrosis, suggesting it as a potential therapeutic target to mitigate fibrosis and enhance cardiac recovery following MI.
format Article
id doaj-art-9e91daf1bf9c403c9fd9abc69bc0160b
institution Kabale University
issn 2772-8927
language English
publishDate 2025-08-01
publisher Elsevier
record_format Article
series Cell Insight
spelling doaj-art-9e91daf1bf9c403c9fd9abc69bc0160b2025-08-20T03:33:06ZengElsevierCell Insight2772-89272025-08-014410025610.1016/j.cellin.2025.100256TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransductionJie Liu0Jingjing Feng1Jingxuan Zhao2Xiangjie Kong3Zhangyi Yu4Yuanru Huang5Zechun He6Mengxin Liu7Zheng Liu8Zhibing Lu9Li Wang10Department of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaThe Institute for Advanced Studies, TaiKang Center for Life and Medical Sciences, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, Hubei , ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, China; Hubei Provincial Clinical Research Center for Cardiovascular Intervention, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, ChinaThe Institute for Advanced Studies, TaiKang Center for Life and Medical Sciences, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Wuhan University, Wuhan 430072, Hubei , ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, China; Hubei Provincial Clinical Research Center for Cardiovascular Intervention, Wuhan 430071, Hubei, ChinaDepartment of Cardiology, Zhongnan Hospital of Wuhan University, Medical Research Institute, Frontier Science Center for Immunology and Metabolism, Wuhan University, Wuhan 430071, Hubei, China; Institute of Myocardial Injury and Repair, Wuhan University, Wuhan 430071, Hubei, China; Corresponding author. Room 1324, 115 Donghu Road, Wuchang District, Wuhan 430071, Hubei, China.Cardiac fibroblast (CF) differentiation into myofibroblasts is a crucial driver of cardiac fibrosis, leading to extensive extracellular matrix (ECM) deposition that increases myocardial stiffness and eventually impairs heart function. Mechanotransduction has merged as a key regulator of CF activation and the fibrotic response post-myocardial infarction (MI). However, the molecular mechanisms linking CF activation to mechanical cues within the injured myocardium remain poorly understood. Here we identified transcription factor TFAP4 as a central regulator of fibrosis in both human and murine models. TFAP4 overexpression enhances CF proliferation, ECM protein expression, and myofibroblast differentiation. Notably, TFAP4 directly activates expression of mechanosensors including Itga11 and Piezo2, which are essential for transmitting mechanical signals that promote CF activation and fibrosis. Silencing Itga11 and Piezo2 reverses the pro-fibrotic effects of TFAP4, while TFAP4 downregulation in vivo reduces fibrosis and improves cardiac function post-MI. These findings identify TFAP4 as a pivotal link between mechanotransduction and fibrosis, suggesting it as a potential therapeutic target to mitigate fibrosis and enhance cardiac recovery following MI.http://www.sciencedirect.com/science/article/pii/S2772892725000306Cardiac fibrosisFibroblast activationMechanotransductionTFAP4
spellingShingle Jie Liu
Jingjing Feng
Jingxuan Zhao
Xiangjie Kong
Zhangyi Yu
Yuanru Huang
Zechun He
Mengxin Liu
Zheng Liu
Zhibing Lu
Li Wang
TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
Cell Insight
Cardiac fibrosis
Fibroblast activation
Mechanotransduction
TFAP4
title TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
title_full TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
title_fullStr TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
title_full_unstemmed TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
title_short TFAP4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
title_sort tfap4 exacerbates pathological cardiac fibrosis by modulating mechanotransduction
topic Cardiac fibrosis
Fibroblast activation
Mechanotransduction
TFAP4
url http://www.sciencedirect.com/science/article/pii/S2772892725000306
work_keys_str_mv AT jieliu tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT jingjingfeng tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT jingxuanzhao tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT xiangjiekong tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT zhangyiyu tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT yuanruhuang tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT zechunhe tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT mengxinliu tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT zhengliu tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT zhibinglu tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction
AT liwang tfap4exacerbatespathologicalcardiacfibrosisbymodulatingmechanotransduction